Jena Lilly
A5048992066- Glioma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Neuroblastoma Research and Treatments
- RNA modifications and cancer
- Medical Imaging Techniques and Applications
- Health, Environment, Cognitive Aging
- Epigenetics and DNA Methylation
- Ethics in Clinical Research
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Chemical Reactions and Isotopes
- Ferroptosis and cancer prognosis
- Radiomics and Machine Learning in Medical Imaging
- Cancer Research and Treatments
- Nutrition, Genetics, and Disease
- Biomedical and Engineering Education
- Radiation Therapy and Dosimetry
- Cancer, Hypoxia, and Metabolism
- Advanced Proteomics Techniques and Applications
- Genomics and Rare Diseases
- Telomeres, Telomerase, and Senescence
- Artificial Intelligence in Healthcare and Education
- Ubiquitin and proteasome pathways
- interferon and immune responses
- Genetic factors in colorectal cancer
Children's Hospital of Philadelphia
2017-2024
Alex's Lemonade Stand Foundation
2022
Brain (Germany)
2022
American Association For Cancer Research
2021
We report a comprehensive proteogenomics analysis, including whole-genome sequencing, RNA and proteomics phosphoproteomics profiling, of 218 tumors across 7 histological types childhood brain cancer: low-grade glioma (n = 93), ependymoma (32), high-grade (25), medulloblastoma (22), ganglioglioma (18), craniopharyngioma (16), atypical teratoid rhabdoid tumor (12). Proteomics data identify common biological themes that span boundaries, suggesting treatments used for one type may be applied...
Pediatric brain tumors are the leading cause of cancer-related death in children United States and contribute a disproportionate number potential years life lost compared to adult cancers. Moreover, survivors frequently suffer long-term side effects, including secondary The Children's Brain Tumor Network (CBTN) is multi-institutional international clinical research consortium created advance therapeutic development through collection rapid distribution biospecimens data via open-science...
Pediatric brain and spinal cancers are collectively the leading disease-related cause of death in children; thus, we urgently need curative therapeutic strategies for these tumors. To accelerate such discoveries, Children's Brain Tumor Network (CBTN) Pacific Neuro-Oncology Consortium (PNOC) created a systematic process tumor biobanking, model generation, sequencing with immediate access to harmonized data. We leverage data establish OpenPBTA, an open collaborative project over 40 scalable...
Real-world data sets that combine clinical and genomic may be subject to left truncation (when potential study participants are not included because they have already passed the milestone of interest at time recruitment). The lapse between diagnosis molecular testing can present analytic challenges threaten validity interpretation survival analyses.Effects ignoring when estimating overall illustrated using from American Association for Cancer Research (AACR) Project Genomics Evidence...
<h3>Importance</h3> Contemporary observational cancer research requires associating genomic biomarkers with reproducible end points; overall survival (OS) is a key point, but interpretation can be challenging when multiple lines of therapy and prolonged are common. Progression-free (PFS), time to treatment discontinuation (TTD), next (TTNT) alternative points, their utility as surrogates for OS in real-world clinicogenomic data sets has not been well characterized. <h3>Objective</h3> To...
Abstract Patients with non-small cell lung cancer (NSCLC) who have distant metastases a poor prognosis. To determine which genomic factors of the primary tumor are associated metastasis, we analyzed data from 759 patients originally diagnosed stage I–III NSCLC as part AACR Project GENIE Biopharma Collaborative consortium. We found that TP53 mutations were significantly development new metastases. also more prevalent in history smoking, suggesting these may be at increased risk for...
Abstract Childhood cancers and structural birth defects share a common context of altered developmental biology, but the potential role shared, genetic alterations and/or pathways across pediatric is not well explored. It increasingly critical that genomic data are paired with high-quality clinical to drive translational research by elucidating relationship between alterations, treatments, outcomes, other phenotypic characteristics. The NIH Common Fund Gabriella Miller Kids First Program...
CAVATICA (cavatica.org) was developed to address the lack of open access large scale pediatric cancer genomic datasets for research community. As first its kind portal, empowers data upload, sharing, and creation pipelines, data, algorithms, visualizations, hypotheses. Building upon need brain tumor genome dataset, Pediatric Brain Tumor Atlas founded in late 2016, a concerted multi-institution effort by Children's Consortium (CBTTC) Pacific Neuro-Oncology Consortium. The goal is characterize...
Summary Pediatric brain and spinal cancer are the leading disease-related cause of death in children, thus we urgently need curative therapeutic strategies for these tumors. To accelerate such discoveries, Children’s Brain Tumor Network Pacific Neuro-Oncology Consortium created a systematic process tumor biobanking, model generation, sequencing with immediate access to harmonized data. We leverage data create OpenPBTA, an open collaborative project which establishes over 40 scalable analysis...
Abstract BACKGROUND Pediatric high grade glioma (pHGG) remains a fatal disease. Access to richly annotated biospecimens and patient derived tumor models will accelerate pHGG research support translation of discoveries. This work describes the pediatric set Children’s Brain Tumor Tissue Consortium (CBTTC) from first release Atlas (PBTA). METHODS tumors with associated clinical data imaging were prospectively collected through CBTTC analyzed as (PBTA) processed genomic deposited into...
ABSTRACT Background Pediatric high grade glioma (pHGG) remains a fatal disease. Increased access to richly annotated biospecimens and patient derived tumor models will accelerate pHGG research support translation of discoveries. This work describes the pediatric set Children’s Brain Tumor Tissue Consortium (CBTTC) from first release (October 2018) Atlas (PBTA). Methods tumors with associated clinical data imaging were prospectively collected through CBTTC analyzed as (PBTA) processed genomic...
INTRODUCTION: The Children’s Brain Tumor Tissue Consortium (CBTTC) is a multi-institutional, international research collaboration comprised of 13 institutions utilizing an infrastructure web based open source tools to accelerate pediatric brain tumor research. CBTTC mission provide the largest accessible, de-identified, longitudinal clinical data set linked available biospecimens and -omic in world. METHODS: Clinical collection protection Personal Health Information (PHI) major regulatory...
Abstract Pediatric central nervous system (CNS) cancers are the leading disease-related cause of death in children and there is urgent need for curative therapeutic strategies these tumors. To address urgency, Children’s Brain Tumor Network (CBTN) has advanced an open science model to accelerate research discovery pediatric brain In first phase Open Atlas (OpenPBTA) effort CBTN together with Pacific Neuro-Oncology Consortium (PNOC) support Gabriella Miller Kids First Data Resource Center...
Abstract BACKGROUND Pediatric brain and spinal cord tumors are the leading cause of cancer-related mortality in children. An incomplete understanding tumor biology associated limited access to high-quality biological samples for research main factors driving lack clinical therapeutic development pediatric that recur or progress. Post-mortem tissue donation provides an unprecedented resource addressing some these limitations. METHODS The Gift from a Child (GFAC) program by Swifty Foundation...
Abstract Since launching to the public in September 2018, Gabriella Miller Kids First Data Resource Center (DRC) has made an increasing number of pediatric genomic studies available research community. Currently, 1.3 PBs and clinical data drawn from 12,000 participants are across a variety cancer structural birth defect studies. The DRC architected secure, cloud-based platform with over 1,300 users that supports ability researchers not only find, access, reuse data, but also integrate,...
Abstract Pediatric brain tumors are the leading cause of disease-related death in children. However, despite large scale data-driven efforts for pediatric cancers by NIH (e.g. TARGET, Therapeutically Applicable Research To Generate Effective Treatments), public access to large-scale tumor genomic data remains limited. As a result, precision medicine initiatives and clinical trials hampered absence publicly available resources that can dynamically inform novel discovery implementation...
Abstract Introduction: The Children’s Brain Tumor Tissue Consortium (CBTTC), an international repository of genomic and phenotypic data, has partnered with Blackfynn, Inc., to create a cloud-based data management platform facilitate team-science across disciplines. Background: CBTTC through the CHOP Department Biomedical Health Informatics (DBHi) developed network informatics applications for researchers globe work together perform real-time analyses on existing clinical, phenotypic, data....
Childhood cancers and structural birth defects share a common context of altered developmental biology, but the potential role shared, genetic alterations and/or pathways across pediatric is not well explored. It increasingly critical that genomic data are paired with high-quality clinical to drive translational research by elucidating relationship between alterations, treatments, outcomes, other phenotypic characteristics. The NIH Common Fund Gabriella Miller Kids First Program represents...
Abstract Pediatric brain tumors are the leading cause of cancer-related death in children United States and contribute a disproportionate number potential years life lost compared to adult cancers. Moreover, survivors frequently suffer long-term side effects, including secondary The Children’s Brain Tumor Network (CBTN) is multi-institutional international clinical research consortium created advance therapeutic development through collection rapid distribution biospecimens data via...
Abstract Pediatric brain tumors comprise a heterogeneous molecular and histological landscape that challenges most current precision-medicine approaches. While recent large-scale efforts to molecularly characterize distinct entities have dramatically advanced the field’s capacity classify further define subtypes, developing therapeutic less toxic molecularly-defined clinical approaches remains challenge. To new meet these advance scalable, shared biospecimen- data-resources for pediatric...
Abstract Brain tumors are the leading cause of disease-related death in children and young adults ages 0-19 largely populated countries such as United States. In one year alone, 4,000 will be diagnosed with a brain or central nervous system tumor complex difficult to treat growing children, current treatments oftentimes causing significant lifelong side effects. Furthermore, there have only been five drugs last 20 years approved by FDA pediatric tumors. Founded 2011, Children’s Tumor Network...
Abstract Pediatric brain tumor preclinical development has suffered from the lack of robust in vitro and vivo models that span large number histologies. Opportunities for precision medicine approaches solid tumors are expanding, including immunotherapies, so it is essential to maximize access studies specificity, efficacy, safety treatments ways align patient samples their clinical course. The Children’s Brain Tumor Network (CBTN) seeks accelerate pediatric research discovery through support...